The FDA has granted Fast Track designation to elritercept (KER-050) for the treatment of anemia in adults with low- or intermediate-risk myelodysplastic syndromes. Elritercept is a fusion protein designed to increase red blood cell production and platelet production. Initial data from a phase 2 trial showed promising results, with 50% of patients achieving an erythroid response. Common side effects included diarrhea, dyspnea, fatigue, nausea, and headache. The Fast Track designation allows for expedited review of the therapy, and plans are in place for a phase 3 clinical trial to further evaluate its effectiveness.
Source link
Elritercept Fast Tracked for Lower-Risk Myelodysplastic Syndromes
